BioinvestGPT

BioinvestGPT ApS · Research use only

NCT06597799 (MRT-6160 in autoimmune diseases): BVCT ex-ante prediction vs. reported outcome

On 3 Nov 2024, BioinvestGPT's BVCT predicted technical success and commercial success for this trial. The 20 Mar 2025 readout is classified on the dashboard as True Positive (TP), a correct prediction. Recorded clinical-benefit conclusion: statistically significant (safety) and commercially TBD.

Clinical Trial

NCTID
NCT06597799
Drug Name
MRT-6160
Drug MoA
anti-VAV1 molecular glue degrader
Drug Modality
molecular glue degrader
Drug Class
First-In-Class
Therapeutic Area
Immune System Diseases
Indication
autoimmune diseases
Human Patients
76
Sponsor
Monte Rosa Therapeutics
Phase
Phase 1

Prediction of , index 1814

Prospective Prediction
Prediction Index
1814
Prediction Date
Commercial Prediction
SUCCESS (commercially sufficient clinical benefit for certain treatment-naïve and treatment-refractory autoimmune diseases superior to the corresponding SoCs)
Technical Prediction
SUCCESS (statistically significant clinical benefit against placebo for certain treatment-naïve and treatment-refractory autoimmune diseases)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
137 days in advance
Readout Data Interpretation
MRT6160 achieved >90% VAV1 degradation
Press Release
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically significant (safety) and commercially TBD
Prediction Classification
True Positive (TP)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
Phase 1, First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Ascending Dose, and Food-Effect Study to Assess Safety, Tolerability, PK and PD of MRT-6160 in Healthy Subjects
Phase
Phase 1
Status
Completed
Enrollment
108
Lead sponsor
Monte Rosa Therapeutics, Inc
Conditions
Healthy Volunteers
Interventions
DRUG: MRT-6160; DRUG: Placebo
Design
Randomized · Sequential · Quadruple
Primary purpose
Treatment
Start
2024-08-07
Primary completion
2025-04-10
Completion
2025-04-10
Primary outcomes
  • To evaluate the safety and tolerability of single ascending doses of MRT-6160 in healthy adult subjects (6 weeks)
  • To evaluate the safety and tolerability of multiple ascending doses of MRT-6160 in healthy adult subjects (7.5 weeks)

NCT06597799 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials